Mirtazapine Sandoz B.V.

Mirtazapine, the active ingredient in Mirtazapine Sandoz B.V., is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Sandoz B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet clinical needs.

Mirtazapine is used primarily in the management of depressive disorders, acting on noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (adjunct): helps alleviate the depressive phase when used with mood stabilizers. - Depression with insomnia: promotes sleep and appetite, supporting recovery in patients with sleep disturbances.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Hepatotoxicity - Seizures - Hyponatremia (SIADH) - Suicidal thoughts, especially early in treatment

When prescribing mirtazapine, clinicians should consider several safety measures and monitoring requirements. - Assess psychiatric history: evaluate risk of suicidal ideation, especially in early treatment. - Monitor weight and metabolic parameters: due to potential weight gain and increased appetite. - Check liver function: use with caution in hepatic impairment. - Review concomitant CNS depressants: increased sedation may occur. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Combined use with other potent CNS depressants (e.g., benzodiazepines, opioids): may cause profound sedation. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome. - Anticholinergic drugs: additive dry mouth. - Alcohol: enhances sedative effect.